The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine. Omeros Corporation's therapeutic advance represents the first and only FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This life-threatening complication has historically lacked effective medical interventions and claimed hundreds of lives annually.
For transplant physicians and their patients, this approval signals a fundamental shift in clinical practice—from managing a fatal disease with supportive measures to wielding a targeted therapy with robust efficacy and sur...
